KYVERNA THERAPEUTICS INC
KYTX · NASDAQ
Updated at 2026-10-15 08:07:21
- Today's High
- $5.84
- Today’s Low
- $5.61
%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23150%3B%26%23135%3B%26%23230%3B%26%23161%3B%26%23163%3B%26%23230%3B%26%23154%3B%26%23151%3B%26%23232%3B%26%23167%3B%26%23146%3B%22%20d%3D%22M48.3363%2013.4132H60.2082L46.795%205.72205e-06V11.8719C46.795%2012.7231%2047.4851%2013.4132%2048.3363%2013.4132Z%22%20fill%3D%22var(--fill-0%2C%20%23474741)%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23148%3B%26%23190%3B%26%23229%3B%26%23164%3B%26%23167%3B%26%23233%3B%26%23149%3B%26%23156%3B%22%20fill-rule%3D%22evenodd%22%20clip-rule%3D%22evenodd%22%20d%3D%22M11.3812%2020.3725C16.7977%2014.9559%2025.5803%2014.9559%2030.9969%2020.3725C36.413%2025.789%2036.4131%2034.5707%2030.9969%2039.9872C26.0109%2044.973%2018.1729%2045.3699%2012.7335%2041.1769L2.54298%2051.3684L0%2048.8254L10.1915%2038.6329C5.99993%2033.1937%206.39609%2025.3579%2011.3812%2020.3725ZM28.4539%2022.9155C24.4418%2018.9033%2017.9363%2018.9033%2013.9241%2022.9155C9.91245%2026.9275%209.91241%2033.4322%2013.9241%2037.4442C17.9362%2041.4562%2024.4418%2041.4562%2028.4539%2037.4442C32.4656%2033.4322%2032.4656%2026.9275%2028.4539%2022.9155Z%22%20fill%3D%22var(--fill-0%2C%20%235D5D56)%22%2F%3E%0A%3C%2Fg%3E%0A%20%20%3C%2Fsvg%3E%0A%3C%2Fsvg%3E%0A)
Candlestick trends are for reference. Refer to the trading page for actual data.
Key Statistics
- Previous Open
- $5.76
- Previous Close
- $5.68
- Volume
- 1.27M
- Market Cap
- $351.58M
- P/E Ratio
- --
- EPS
- $-2.93
Previous Day Range
52-Week Range
Company Overview
- Sector
- HEALTHCARE
- Industry
- Biotechnology
- Sub-industry
- BIOTECHNOLOGY
- Headquarters
- 5980 HORTON STREET, EMERYVILLE, CA, UNITED STATES, 94608
- Country
- US
- Listing Date
- 2024-02-08
- Fiscal Year End
- December
- Shares Outstanding
- 60.8M
- CIK
- 0001994702
- Website
- kyvernatx.com
Kyverna Therapeutics, Inc. is an innovative biotechnology company focused on advancing immunotherapies for autoimmune diseases and other significant health challenges. Employing its proprietary genetically engineered T-cell technology, Kyverna aims to enhance the functionality of the immune system, offering specialized cellular therapies designed to improve patient outcomes substantially. With its commitment to developing cutting-edge therapeutic solutions and its strategic positioning within the growing biopharmaceutical sector, the company presents an appealing opportunity for institutional investors interested in the transformative potential of immunotherapy.
Financial Metrics
Revenue
2026-06-30
$0
2026-03-31
$0
2025-12-31
$0
2025-09-30
$0
Operating Expenses
2026-06-30
$39.55M
2026-03-31
$41.01M
2025-12-31
$39.28M
2025-09-30
$38.72M
Net Income
2026-06-30
-$38.31M
2026-03-31
-$39.72M
2025-12-31
-$37.8M
2025-09-30
-$36.78M
Net Profit Margin
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
--
Earnings Per Share
2026-06-30
$-0.63
2026-03-31
$-0.65
2025-12-31
$-0.80
2025-09-30
$-0.85
Earnings Before Interest, Taxes, Depreciation, and Amortization
2026-06-30
-$37.21M
2026-03-31
-$38.71M
2025-12-31
-$36.99M
2025-09-30
-$36.36M
Effective Tax Rate
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
--
| Item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Operating Expenses | $39.55M | $41.01M | $39.28M | $38.72M |
| Net Income | -$38.31M | -$39.72M | -$37.8M | -$36.78M |
| Net Profit Margin | -- | -- | -- | -- |
| Earnings Per Share | $-0.63 | $-0.65 | $-0.80 | $-0.85 |
| Earnings Before Interest, Taxes, Depreciation, and Amortization | -$37.21M | -$38.71M | -$36.99M | -$36.36M |
| Effective Tax Rate | -- | -- | -- | -- |
FAQs
Risk Warning
Stock prices can be highly volatile and may rise or fall sharply in a short period. Digital asset and derivative products involve additional risks such as leverage and liquidity. Content on this page is for reference only and does not constitute investment advice. Product availability and access may vary by region and applicable regulations.